Gene Synthesis Market Report: Trends & 2033 Forecast

The global Gene Synthesis Services Market is projected to expand from USD 2.7 billion in 2025 to approximately USD 9.3 billion by 2033, registering a compound annual growth rate (CAGR) of 16.7%. Growth is anchored by falling per-base synthesis costs, expanding applications in antibody discovery, and the maturation of automated platform technologies. The Gene & Cell Therapy Development Market is the largest application vertical, contributing nearly 40% of end-use revenue, followed by vaccine construction and diagnostic assay prototyping.

Across regions, North America leads with a 38% value share, supported by strong biotech funding and regulatory clarity for synthetic DNA products. Europe follows at 28%, while Asia-Pacific is the fastest-growing geography with a projected CAGR of 19.4%. A notable shift is occurring in procurement patterns: contract research organizations and biotech developers are increasing order volumes and requiring shorter lead times for complex constructs. This is creating sustained momentum for the Custom Gene Synthesis Market and forcing vendors to differentiate on fidelity, scalability, and sequence screening compliance.

The report’s method-level assessment shows that conventional approaches still handle a majority of output, but newer enzymatic and chip-based platforms are eroding share in high-throughput and long-gene projects. Downstream, the Gene & Cell Therapy Development Market drives demand for vector-ready DNA fragments, while vaccine programs require viral gene synthesis with tight technical specifications. These trends will shape competitive strategy and capacity investment through 2033.

The Solid-phase Gene Synthesis Market remains the largest methodology segment, capturing approximately 62% of global gene synthesis revenue in 2025. Solid-phase synthesis is preferred for its mature phosphoramidite chemistry, excellent coupling efficiency, and compatibility with existing oligonucleotide synthesizers. It is the standard process for producing gene fragments up to 3–5 kb, and it underpins reagent and consumable sales in the broader Oligonucleotide Synthesis Market.

Within solid-phase workflows, column-based formats account for roughly 78% of segment revenue, while array-based formats are gaining traction in multiplex library generation. The Chip-based Gene Synthesis Market is expanding at a 22% CAGR, enabled by silicon microarrays and electrochemical deprotection. In parallel, the PCR-based Enzyme Synthesis Market is promising for long-gene assembly, with enzymatic end-joining reducing cloning time by up to 50%. These two approaches are not yet replacements, but they are changing the cost curve in high-throughput laboratories.

The Solid-phase Gene Synthesis Market will retain majority share through 2033, but its rate of growth is forecast to be 14.5% annually versus 24.0% for chip-based approaches. Margin pressure is emerging from enzymatic synthesis players offering lower cost per base for fragments >2 kb. Leading vendors now offer hybrid workflows that combine solid-phase synthesis for short oligos and chip-based synthesis for complex gene libraries. This convergence expands the total addressable volume and avoids pricing commoditization in the Custom Gene Synthesis Market.

Demand from the Gene & Cell Therapy Development Market is the strongest demand-side catalyst. More than 3,000 active clinical trials involved gene-modified cell therapies in 2025, and each requires cloning fragments, promoter cassettes, and guide RNAs produced by gene synthesis vendors. The Vaccine Development Market is similarly expanding, with new mRNA and protein-based vaccines requiring alternative antigen sequences to tackle viral variants.

Cost efficiency is the second major driver. Average prices for standard gene fragments have declined from $0.10 per base pair in 2020 to approximately $0.04 per base pair in 2025. This price drop allows academic labs and agricultural biotech companies to adopt synthetic DNA at scale. Vendor-level automation, liquid handling robotics, and next-generation sequencing-based quality control are reducing manual labor and accelerating cycle times.

Regulatory compliance is a rising barrier. The U.S. Biosecurity Executive Order and European Commission proposals require synthetic gene providers to screen orders against pathogen databases. Compliance costs are disproportionately burdensome for smaller vendors in the Gene Synthesis Services Market, and this may slow new entry. Intellectual property disputes around enzymatic synthesis and error-correction enzymes also limit licensing options for the PCR-based Enzyme Synthesis Market's expansion.

Supply chain concentration is another restraint. Specialty reagents, including engineered polymerases and controlled pore glass beads, are sourced from a limited number of upstream manufacturers. Any disruption can postpone delivery timelines and create order backlogs. The open-source biofoundry movement is attempting to mitigate this by promoting standardized reagents and modular workflows, but broad adoption remains 3–5 years out.

• Twist Bioscience: A silicon-based DNA synthesis leader, Twist Bioscience scales production through high-density microarrays and supplies gene fragments, oligo pools, and library preparations to the gene therapy and vaccine sectors.
• GenScript Biotech: GenScript provides a broad gene-to-protein workflow, with gene synthesis capacity in China, the U.S., and Europe. Its integrated plasmid manufacturing and express-on-demand protein services create strong cross-selling opportunities.
• Thermo Fisher Scientific: Through GeneArt and custom DNA services, Thermo Fisher offers traceable, GMP-compatible synthetic genes for clinical-stage developers, alongside a large catalogue of molecular biology reagents.
• Integrated DNA Technologies (IDT): IDT is a major producer of gBlocks gene fragments and custom primers, widely used in NGS and CRISPR workflows. Its high-fidelity synthesis and fast turnaround support genomics discovery.
• Eurofins Scientific: Eurofins operates multiple genomics laboratories, providing sequence-verified synthetic genes and plasmid services. Its decentralized lab network supports regional delivery in Europe and North America.
• BGI Genomics: BGI supplies gene synthesis and plasmid preparation at large-scale, leveraging automated production lines and low-cost manufacturing to serve global research organizations.
• Azenta Life Sciences: Azenta’s gene synthesis business focuses on clinical research and biobanking sectors, providing gene editing tools and synthetic DNA with robust sample tracking.

• March 2025: Twist Bioscience expanded its silicon microarray manufacturing capacity by 25%, targeting increased output of synthetic genes for antibody discovery.
• January 2025: GenScript introduced an automated gene synthesis pipeline that cuts turnaround time for complex constructs from 15 days to 8 days.
• November 2024: Thermo Fisher Scientific opened a new oligonucleotide production facility in California to support growing gene synthesis demand from the Vaccine Development Market.
• August 2024: Integrated DNA Technologies enhanced its gBlocks validation workflow using long-read nanopore sequencing to improve error-free construct delivery.
• May 2024: BGI Genomics partnered with academic institutes in Singapore to develop low-cost whole-genome synthesis protocols for industrial enzymes.
• February 2024: Azenta Life Sciences completed a series of automation upgrades at its New Jersey gene synthesis facility, reducing manual handling and improving throughput.
• October 2023: Eurofins launched a new sequence-confirmed clone delivery service for cell and gene therapy research, emphasizing full plasmid traceability.

North America is the most mature gene synthesis market, holding a 38% share in 2025. The United States retains the largest installed base of biofoundries, with public funding for pandemic preparedness and synthetic biology research driving demand. Canada and Mexico contribute through industrial genomics programs, although at smaller volumes. North America’s CAGR is projected at 15.8%, slower than emerging regions but supported by high-value clinical-grade orders.

Europe represents the second-largest regional market with a 28% share. The United Kingdom, Germany, France, and Switzerland lead in cell and gene therapy research, while EU-funded synthetic biology projects have increased demand for sequence-verified clones. The regional CAGR is forecast at 16.3%. Regulatory alignment under the European Medicines Agency supports late-stage clinical use of synthetic DNA.

Asia-Pacific is the fastest-growing region, expanding at a 19.4% CAGR. China’s investments in biomanufacturing and BGI’s gene factory scale provide low-cost capacity. Japan’s regenerative medicine pipeline and Korea’s vaccine development programs add demand. India’s contract research sector is also increasing outsourcing of gene synthesis services. By 2033, Asia-Pacific is expected to overtake Europe as the second-largest market region.

South America and the Middle East & Africa collectively represent 10% of the market. Brazil and Argentina are building genomics infrastructure for agricultural gene editing, while GCC nations are investing in vaccine manufacturing capabilities. South Africa’s health biotechnology sector is creating incremental demand for diagnostic gene targets. These regions will remain niche but exhibit compound annual growth rates near 15% from a small base.

Capital formation in the gene synthesis sector has accelerated as synthetic biology converges with biopharmaceutical manufacturing. Global synthetic biology venture financing reached $7.4 billion in 2024, with approximately 28% allocated to DNA synthesis and assembly technologies. In 2023, private equity investors funded enzymatic DNA synthesis startups, attracted by the potential to lower raw material cost and improve sustainability.

M&A activity has centered on acquiring intellectual property in chip-based synthesis and error-correction. In 2024, a large chromatography and life sciences platform acquired a portfolio of microarray-based gene synthesis patents, underscoring the strategic value of upstream process patents. Public gene synthesis companies have also used follow-on offerings to fund capacity expansions, particularly in silicon-based manufacturing.

High-growth sub-segments attracting capital include long-gene synthesis, whole-plasmid assembly, and biofoundry automation. Investors favor vendors that combine synthetic biology tools with laboratory informatics, because software-enabled services can command recurring revenue and drive stickiness across customer workflows.

Enzymatic DNA synthesis (EDS) is the most publicized disruptive technology. By using engineered polymerases and reversible terminator nucleotides, EDS avoids hazardous organic solvents and reduces the cost per base for long genes. Commercial GMP-compliant EDS platforms are expected to reach broad adoption by 2027, particularly in the Gene & Cell Therapy Development Market, where high-fidelity constructs are essential.

Chip-based synthesis is advancing in parallel, driven by silicon microarrays and photochemistry. The Chip-based Gene Synthesis Market is projected to remain the fastest-growing method segment, with applications in CRISPR library construction and affordable whole-genome synthesis. Patent counts for chip-based synthesis methods increased by 28% annually between 2020 and 2024, indicating a crowded research front and potential litigation risk.

Integration of artificial intelligence and laboratory automation is the third trajectory. Machine learning algorithms now predict secondary structures and disfavored repeats, improving clone success rates. Combined with modular benchtop synthesizers, these advances are lowering the barriers to self-sufficiency in core facilities. The broader Oligonucleotide Synthesis Market expansion reinforces incumbent oligo suppliers, while the Synthetic Biology Tools Market creates opportunity for software and instrument vendors. R&D spending among top gene synthesis vendors averages 18% of revenue, sustaining a high cadence of product updates through 2033.

• 1. Method
  • 1.1. Solid-phase Synthesis
  • 1.2. Chip-based Synthesis
  • 1.3. PCR-based Enzyme Synthesis
• 2. Services
  • 2.1. Antibody DNA Synthesis
  • 2.2. Viral DNA Synthesis
  • 2.3. Others
• 3. Application
  • 3.1. Gene & Cell Therapy Development
  • 3.2. Vaccine Development
  • 3.3. Disease Diagnosis
  • 3.4. Others
• 4. End-use
  • 4.1. Biotechnology & Pharmaceutical Companies
  • 4.2. Academic & Government Research Institutes
  • 4.3. Contract Research Organizations

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific